Open Access Repository

Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial

Lintzeris, N, Mills, L, Dunlop, A, Copeland, J, Mcgregor, I, Bruno, R ORCID: 0000-0001-6673-833X, Kirby, A, Montebello, M, Hall, M, Jefferies, M, Kevin, R and Bhardwaj, R 2020 , 'Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial' , Drug and Alcohol Dependence: An International Journal on Biomedical and Psychosocial Approaches, vol. 215 , doi: 10.1016/j.drugalcdep.2020.108220.

Full text not available from this repository.

Abstract

Introduction and Aims: Previous studies suggest cannabinoid agonist treatment is effective in reducing cannabisuse in dependent treatment seekers, however few studies have reported on post-treatment outcomes. We examine cannabis use outcomes 12 weeks after cessation of treatment from a randomised placebo-controlled trialof nabiximols for the treatment of cannabis dependence.Method: 128 participants received either nabiximols (n = 61) or placebo (n = 67) for 12 weeks, in combinationwith psychosocial interventions. Self-reported number of days of cannabis use in the previous 28 days wasmeasured at baseline, 4, 8, and 12 weeks (end of treatment) and again at 24 weeks (3 months after treatmentceased). Urinalysis was used to confirm self-report data at Week 24 interview.Results: A factorial mixed-effects model for repeated measures regression revealed that the nabiximols groupused cannabis on 6.8 fewer days in the previous 28 days at week 12 (end of treatment) than the placebo group (p= 0.002, CI: 2.1,11.4), and 6.7 fewer days in the previous 28 days at the week-24 follow-up than the placebogroup (p = 0.006, CI: 1.4,12.1). A significantly higher proportion of the nabiximols group (14/61; 23 %) thanthe placebo group (6/67; 9%) reported abstinence from cannabis in the previous 28 days at the week-24 researchinterview OR=3.0, CI: 1.1, 9.1; p=0.035, NNT=8, CI: 4, 71).Discussions and Conclusions: The benefits of treatment incorporating nabiximols with psychosocial interventionsin reducing cannabis use appears to persist for up to 3 months after the cessation of treatment. A stepped caremodel of treatment is proposed

Item Type: Article
Authors/Creators:Lintzeris, N and Mills, L and Dunlop, A and Copeland, J and Mcgregor, I and Bruno, R and Kirby, A and Montebello, M and Hall, M and Jefferies, M and Kevin, R and Bhardwaj, R
Keywords: cannabis dependence, cannabis use disorder, nabiximols, RCT, treatment, outcomes
Journal or Publication Title: Drug and Alcohol Dependence: An International Journal on Biomedical and Psychosocial Approaches
Publisher: Elsevier Sci Ireland Ltd
ISSN: 0376-8716
DOI / ID Number: 10.1016/j.drugalcdep.2020.108220
Copyright Information:

Copyright 2020 Elsevier B.V

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP